Clinical Trials Arena on MSN5d
Mixed data results for two Monte Rosa molecular glue degradersMonte Rosa has unveiled new data from two trials of its pipeline of molecular glue degraders, notably MRT-6160 and MRT-23.
Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s ...
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025Ongoing Phase 3 ...
Monte Rosa's in-house pipeline is led by MRT-2359, a molecular glue degrader that breaks down a protein called GSPT1 and is in phase 1/2 trials as a potential treatment for lung cancer and other ...
Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...
Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...
Northwestern Medicine investigators have uncovered new insights into how intercellular "glue" functions to enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback